Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Feyz-Journal of Kashan University of Medical Sciences. 2013; 17 (2): 123-131
em Persa | IMEMR | ID: emr-130275

RESUMO

Considering the effectiveness of nebulized furosemide in asthma crisis that were non-responsive to the inhalational beta-agonists, this study aimed to examine the effect of concomitant administration of furosemide [10 mg] and nebulized salbutamol [2.5 mg] on spirometry parameters in persistent asthma. In this clinical trial, 53 patients [age, 18-75 years] with a 6-months history of persistent asthma were randomly allocated to two groups, the salbutamol [n=27] and salbutamol + furosemide [n=26] groups. Participants in each group were classified into the mild, moderate and severe persistent asthma on the basis of FEV1. Participants were administered salbutamol or salbutamol + furosemide, and then the spirometry parameters were recorded 15 minutes after the completion of nebulization treatment. Before and after the treatment, mean and standard deviation of the spirometry parameters and their changes were calculated. Results showed no significant difference regarding the mean percentage change for FEV1 in the salbutamol [27.5%] and salbutamol + furosemide groups [25.83%] after the treatment [P=0.72]. Moreover, no significant difference was seen between the two groups regarding the mean percentage changes in other parameters after the treatment [FVC, FEV1, PEF, MMEF, FEV1/FVC, P>0.25]. Concomitant administration of furosemide and salbutamol has no advantage over salbutamol in normalizing the spirometry parameters of persistent asthma


Assuntos
Humanos , Feminino , Masculino , Asma/fisiopatologia , Espirometria , Furosemida , Albuterol , Quimioterapia Combinada , Furosemida/administração & dosagem
2.
Feyz-Journal of Kashan University of Medical Sciences. 2013; 17 (2): 220-224
em Persa | IMEMR | ID: emr-130286

RESUMO

Renal cell carcinoma [RCC] is responsible for 90-95% of malignant renal neoplasms. Peak incidence is between the 5[th] and 7[th]decades of life. Metastatic RCC to the breast is extremely rare. A 55-year-old woman presented with a mass in her right breast. Mammography demonstrated a 22x32 mm mass with increased density associated with spiculation and microcalcification areas. Biopsy of the mass reported an invasive ductal carcinoma. During the evaluation of metastasis and staging, another mass [38x33x27 mm] was detected in the inferior pole of the right kidney with heterogeneous appearance. Nephrectomy was performed and the pathological evaluation of the kidney mass reported a clear cell renal carcinoma. Breast mass was vimentin-positive carcinoma that was consistent with metastasis from RCC. Breast metastasis from RCC was diagnosed and the patient treated with immunotherapy [Interferon alfa]. It can be concluded that the breast tissue can be a site for RCC metastasis. Therefore, after detecting a malignant breast mass, a comprehensive evaluation is necessary to differentiate between the primary and metastatic breast cancers


Assuntos
Humanos , Feminino , Neoplasias Renais , Metástase Neoplásica , Carcinoma de Células Renais/complicações , Doenças Raras , Mamografia , Incidência , Neoplasias da Mama/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA